| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 1.620.333 $ | +875.902 $ | +2,0 % | 9 | 4.024.354 $ | +472.206 $ | -8,1 % | 7 | 4.279.210 $ | +536.765 $ | +29,4 % | 11 | 22.859.400 $ | +13.006.269 $ | +55,7 % | 12 | ||||
| Rezolute, Inc. | RZLT | → 0 | Neutral | 18.676.089 $ | +11.522.311 $ | +161,1 % | 1 | ||||||||||||
| SPDR GOLD TRUST | GLD | → 0 | 3.279.923 $ | +520.022 $ | +18,8 % | 1 | 2.759.901 $ | +169.965 $ | +6,6 % | 1 | 2.589.936 $ | +1.080.396 $ | +71,6 % | 1 | |||||
| SPACE EXPLORATION TECHNOLOGIES CORP | SPCX | → 0 | 445.346 $ | +445.346 $ | 1 | ||||||||||||||
| BERKSHIRE HATHAWAY INC | BRK-B | → 0 | Neutral | 377.128 $ | +28.787 $ | +8,3 % | 1 | 348.341 $ | -8.430 $ | -2,4 % | 1 | 356.771 $ | +29.317 $ | +9,0 % | 1 | 327.454 $ | +20.414 $ | +6,6 % | 1 |
| Definium Therapeutics, Inc. | DFTX | → 0 | Neutral | 210.058 $ | -108.401 $ | -34,0 % | 1 | 318.459 $ | +97.325 $ | +44,0 % | 1 | ||||||||
| Spyre Therapeutics, Inc. | SYRE | → 0 | Neutral | 292.194 $ | +292.194 $ | 1 | |||||||||||||
| Enliven Therapeutics, Inc. | ELVN | → 0 | Neutral | 268.106 $ | +5.370 $ | +2,0 % | 1 | ||||||||||||
| Alphabet Inc. | GOOGL | → 0 | Neutral | 246.906 $ | +246.906 $ | 1 | |||||||||||||
| Blackstone Inc. | BX | → 0 | Stark | 188.218 $ | +188.218 $ | 1 | |||||||||||||
| Compass Therapeutics, Inc. | CMPX | → 0 | Neutral | 158.386 $ | -28.874 $ | -15,4 % | 1 | 187.260 $ | +74.250 $ | +65,7 % | 1 | ||||||||
| Kyverna Therapeutics, Inc. | KYTX | → 0 | Neutral | 110.009 $ | -52.003 $ | -32,1 % | 1 | 162.012 $ | -14.456 $ | -8,2 % | 1 | 176.468 $ | +38.581 $ | +28,0 % | 1 | 137.887 $ | +67.335 $ | +95,4 % | 1 |
| Bicara Therapeutics Inc. | BCAX | → 0 | Schwach | 172.760 $ | +71.117 $ | +70,0 % | 1 | ||||||||||||
| Lexeo Therapeutics, Inc. | LXEO | → 0 | Neutral | 78.959 $ | -1.073 $ | -1,3 % | 1 | 80.032 $ | -58.421 $ | -42,2 % | 1 | 138.453 $ | +23.369 $ | +20,3 % | 1 | 115.084 $ | +45.410 $ | +65,2 % | 1 |
| X4 Pharmaceuticals, Inc | XFOR | → 0 | Neutral | 72.650 $ | +8.401 $ | +13,1 % | 1 | 64.249 $ | +2.022 $ | +3,2 % | 1 | 62.227 $ | +62.227 $ | 1 | |||||
| Inhibikase Therapeutics, Inc. | IKT | → 0 | Schwach | 57.759 $ | +9.958 $ | +20,8 % | 1 | 47.801 $ | -10.527 $ | -18,0 % | 1 | 58.328 $ | +31.771 $ | +119,6 % | 1 | 26.557 $ | -5.409 $ | -16,9 % | 1 |
| ALX ONCOLOGY HOLDINGS INC | ALXO | → 0 | Neutral | 43.358 $ | +1.362 $ | +3,2 % | 1 | 41.996 $ | +41.996 $ | 1 | |||||||||
| SAB Biotherapeutics, Inc. | SABS | → 0 | Neutral | 39.371 $ | +17.392 $ | +79,1 % | 1 | 21.979 $ | +21.979 $ | 1 | |||||||||
| Context Therapeutics Inc. | CNTX | → 0 | Neutral | 27.053 $ | +9.224 $ | +51,7 % | 1 | 17.829 $ | +5.771 $ | +47,9 % | 1 | ||||||||
| 1.620.333 $ | +875.902 $ | +2,0 % | 9 | 4.024.354 $ | +472.206 $ | -8,1 % | 7 | 4.279.210 $ | +536.765 $ | +29,4 % | 11 | 22.859.400 $ | +13.006.269 $ | +55,7 % | 12 | ||||